Advertisement

Effects of anti-osteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures: a retrospective analysis of prospectively designed study

  • H.-K. Min
  • J.-H. Ahn
  • K.-Y. Ha
  • Y.-H. KimEmail author
  • S.-I. Kim
  • H.-Y. Park
  • K.-W. Rhyu
  • Y.-Y. Kim
  • I.-S. Oh
  • J.-Y. Seo
  • D.-G. Chang
  • J.-H. Cho
Original Article
  • 162 Downloads

Abstract

Summary

Effects of anti-osteoporosis medications such as anti-resorptive and anabolic agents on healing of osteoporotic spinal fracture were retrospectively investigated. The use of anabolic agent significantly enhanced fracture healing, reduced progressive collapse, and presented good pain relief. These findings suggest that proper selection of medication could improve initial management of acute osteoporotic spinal fractures (OSFs).

Introduction

Although anti-osteoporosis medications have beneficial effects on prevention of osteoporotic spinal fractures (OSFs), few studies have compared effects of medications on fracture healing following OSFs. Therefore, the purpose of this study was to elucidate the effects of different anti-osteoporosis medications on radiological and clinical outcomes after acute OSFs.

Methods

A total of 132 patients diagnosed with acute OSFs were enrolled and allocated into three groups [group I (n = 39, no anti-osteoporosis medication), group II (n = 66, bisphosphonate), and group III (n = 27, parathyroid hormone (PTH)]. Radiological parameters including magnetic resonance (MR) classification, occurrence of intravertebral cleft (IVC), and clinical outcomes such as numerical rating scale (NRS) and Oswestry disability index were assessed. Risk analyses for IVC and progressive collapse were done along the related factors and medication type.

Results

IVC sign was observed in 30 patients. The rate of IVC sign was lower in group III (7.4%) than that in group I (20.5%) or group II (30.3%), although the difference was not statistically significant. Moreover, the degree of NRS improvement was better in group III than that in group I or group II (5.7 vs. 3.1 vs. 3.5, p < 0.001). On multiple regression analysis, mid-portion type fracture in MR classification was a significant risk factor for progressive OSFs. The use of PTH showed significant lower incidences of occurrence of IVC (odds ratio (OR) = 0.160) and increase in height loss (OR = 0.325).

Conclusions

Different anti-osteoporosis medications presented different clinical and radiological results after acute OSFs. The use of anabolic agent significantly enhanced fracture healing, reduced progressive collapse, and presented better clinical outcomes. Proper selection of medication might improve initial management of acute OSFs.

Keywords

Bisphosphonates Nonunion Osteoporosis Osteoporotic spinal fractures Teriparatide 

Notes

Funding

This study was partially supported by investigator initiated trial funded by Dong-A Pharmaceuticals.

Compliance with ethical standards

Conflicts of interest

None.

Ethical issues

This study was performed through retrospective analysis of clinical and radiological data. Approval of institutional review board was obtained before this submission.

References

  1. 1.
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465–475CrossRefPubMedGoogle Scholar
  2. 2.
    Ballane G, Cauley JA, Luckey MM, El-Hajj Fuleihan G (2017) Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int 28:1531–1542CrossRefPubMedGoogle Scholar
  3. 3.
    Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541CrossRefPubMedGoogle Scholar
  4. 4.
    Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30:934–944CrossRefGoogle Scholar
  5. 5.
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124CrossRefPubMedGoogle Scholar
  6. 6.
    Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N (2016) A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess 20:1–406CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Endo Y, Kumamoto H, Nakamura M, Sugawara S, Takano-Yamamoto T, Sasaki K, Takahashi T (2017) Underlying mechanisms and therapeutic strategies for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Biol Pharm Bull 40:739–750CrossRefPubMedGoogle Scholar
  8. 8.
    Schilcher J, Koeppen V, Aspenberg P, Michaelsson K (2015) Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 86:100–107CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Colon-Emeric C, Nordsletten L, Olson S et al (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 22:2329–2336CrossRefPubMedGoogle Scholar
  10. 10.
    Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML (2009) Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am 34:595–602CrossRefPubMedGoogle Scholar
  11. 11.
    Matos MA, Tannuri U, Guarniero R (2010) The effect of zoledronate during bone healing. J Orthop Traumatol 11:7–12CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Saito M, Shiraishi A, Ito M, Sakai S, Hayakawa N, Mihara M, Marumo K (2010) Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 46:1170–1179CrossRefPubMedGoogle Scholar
  13. 13.
    Ha KY, Park KS, Kim SI, Kim YH (2016) Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing? Osteoporos Int 27:483–488CrossRefPubMedGoogle Scholar
  14. 14.
    Potts JT (2005) Parathyroid hormone: past and present. J Endocrinol 187:311–325CrossRefPubMedGoogle Scholar
  15. 15.
    Kraenzlin ME, Meier C (2011) Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7:647–656CrossRefPubMedGoogle Scholar
  16. 16.
    Aspenberg P, Johansson T (2010) Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 81:234–236CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Peichl P, Holzer LA, Maier R, Holzer G (2011) Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93:1583–1587CrossRefPubMedGoogle Scholar
  18. 18.
    Tsuchie H, Miyakoshi N, Kasukawa Y, Nishi T, Abe H, Segawa T, Shimada Y (2016) The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture. J Bone Miner Metab 34:86–91CrossRefPubMedGoogle Scholar
  19. 19.
    Langdahl BL, Ljunggren O, Benhamou CL, Marin F, Kapetanos G, Kocjan T, Lespessailles E, Napoli N, Nikolic T, Petto H, Moll T, Lindh E (2016) Fracture rate, quality of life and Back pain in patients with osteoporosis treated with Teriparatide: 24-month results from the extended Forsteo observational study (ExFOS). Calcif Tissue Int 99:259–271CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nevitt MC, Chen P, Kiel DP, Reginster JY, Dore RK, Zanchetta JR, Glass EV, Krege JH (2006) Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 17:1630–1637CrossRefPubMedGoogle Scholar
  21. 21.
    Ha KY, Kim YH (2013) Risk factors affecting progressive collapse of acute osteoporotic spinal fractures. Osteoporos Int 24:1207–1213CrossRefPubMedGoogle Scholar
  22. 22.
    Jahng JS, Kim HW (2000) Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Orthopedics 23:1089–1094PubMedGoogle Scholar
  23. 23.
    Nozaka K, Miyakoshi N, Kasukawa Y, Maekawa S, Noguchi H, Shimada Y (2008) Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. Bone 42:90–97CrossRefPubMedGoogle Scholar
  24. 24.
    Seki S, Hirano N, Kawaguchi Y, Nakano M, Yasuda T, Suzuki K, Watanabe K, Makino H, Kanamori M, Kimura T (2017) Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis. Eur Spine J 26:2121–2127CrossRefPubMedGoogle Scholar
  25. 25.
    Ha YC, Park YG, Nam KW, Kim SR (2015) Trend in hip fracture incidence and mortality in Korea: a prospective cohort study from 2002 to 2011. J Korean Med Sci 30:483–488CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Aspenberg P, Malouf J, Tarantino U, García-Hernández PA, Corradini C, Overgaard S, Stepan JJ, Borris L, Lespessailles E, Frihagen F, Papavasiliou K, Petto H, Caeiro JR, Marin F (2016) Effects of Teriparatide compared with risedronate on recovery after pertrochanteric hip fracture: results of a randomized, active-controlled, double-blind clinical trial at 26 weeks. J Bone Joint Surg Am 98:1868–1878CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sudo H, Ito M, Abumi K, Kotani Y, Takahata M, Hojo Y, Minami A (2010) One-stage posterior instrumentation surgery for the treatment of osteoporotic vertebral collapse with neurological deficits. Eur Spine J 19:907–915CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yasuda H, Hoshino M, Tsujio T et al (2017) Difference of clinical course between cases with bone union and those with delayed union following osteoporotic vertebral fractures. Arch Osteoporos 13:3CrossRefPubMedGoogle Scholar
  29. 29.
    Nakamae T, Fujimoto Y, Yamada K, Hiramatsu T, Hashimoto T, Olmarker K, Adachi N (2017) Relationship between clinical symptoms of osteoporotic vertebral fracture with intravertebral cleft and radiographic findings. J Orthop Sci 22:201–206CrossRefPubMedGoogle Scholar
  30. 30.
    Ha KY, Kim YH, Chang DG, Son IN, Kim KW, Kim SE (2013) Causes of late revision surgery after bone cement augmentation in osteoporotic vertebral compression fractures. Asian Spine J 7:294–300CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Kim YC, Kim YH, Ha KY (2014) Pathomechanism of intravertebral clefts in osteoporotic compression fractures of the spine. Spine J 14:659–666CrossRefPubMedGoogle Scholar
  32. 32.
    Libicher M, Appelt A, Berger I, Baier M, Meeder PJ, Grafe I, Dafonseca K, Noldge G, Kasperk C (2007) The intravertebral vacuum phenomen as specific sign of osteonecrosis in vertebral compression fractures: results from a radiological and histological study. Eur Radiol 17:2248–2252CrossRefPubMedGoogle Scholar
  33. 33.
    Fabbriciani G, Pirro M, Floridi P, Callarelli L, Manfredelli MR, Scarponi AM, Mannarino E (2012) Osteoanabolic therapy: a non-surgical option of treatment for Kummell’s disease? Rheumatol Int 32:1371–1374CrossRefPubMedGoogle Scholar
  34. 34.
    Iwata A, Kanayama M, Oha F, Hashimoto T, Iwasaki N (2017) Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: a retrospective comparative study. BMC Musculoskelet Disord 18:148CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141–2150CrossRefPubMedGoogle Scholar
  36. 36.
    Kitaguchi K, Kashii M, Ebina K, Sasaki S, Tsukamoto Y, Yoshikawa H, Murase T (2019) Effects of weekly teriparatide administration for vertebral stability and bony union in patients with acute osteoporotic vertebral fractures. Asian Spine J.  https://doi.org/10.1007/s00198-019-05111-6
  37. 37.
    Dohke T, Iba K, Hanaka M, Kanaya K, Okazaki S, Yamashita T (2018) Teriparatide rapidly improves pain-like behavior in ovariectomized mice in association with the downregulation of inflammatory cytokine expression. J Bone Miner Metab 36:499–507CrossRefPubMedGoogle Scholar
  38. 38.
    Park HY, Ahn JH, Ha KY, Kim YH, Kim SI, Min HK, Oh IS, Seo JY, Park SH (2018) Clinical and radiologic features of osteoporotic spine fracture with delayed neurologic compromises. World Neurosurg 120:e1295–e1300CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  1. 1.Department of Orthopedic Surgery, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  2. 2.Department of Orthopedic SurgeryMediplex Sejong HospitalIncheonSouth Korea
  3. 3.Department of Orthopedic Surgery, St. Vincent Hospital, College of MedicineThe Catholic University of KoreaSuwonSouth Korea
  4. 4.Department of Orthopedic Surgery, Daejeon St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaDaejeonSouth Korea
  5. 5.Department of Orthopedic Surgery, Incheon St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaIncheonSouth Korea
  6. 6.Department of Orthopedic Surgery, Jeju National University Hospital, School of MedicineJeju National UniversityJejuSouth Korea
  7. 7.Department of Orthopedic Surgery, Sanggye Paik Hospital, College of MedicineThe Inje UniversitySeoulSouth Korea

Personalised recommendations